FKIQX Performance — Franklin Income Fund, Class A
Data updated: 2026-08-27
FKIQX returned +4.71% year to date and +11.43% over one year to Jun 2026. Annualised returns are +9.58% over 3 years and +6.27% over 5 years. The fund trailed its Moderate Allocation category average: $100 invested three years ago grew to $132, against $141 for the category, and to $111 over one year, against $115. Volatility over the past three years was 7.06% a year. In the 12 months to Jun 2026 the fund took in a net $938.4M, and assets reached $79.23B.
FKIQX Growth of $100
What $100 invested in Franklin Income Fund grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Moderate Allocation category average over the same months.
| Period | FKIQX | Category average |
|---|---|---|
| 1 year (Jul 2025 – Jun 2026) | $111 | $115 |
| 3 years (Jul 2023 – Jun 2026) | $132 | $141 |
| 5 years (Jul 2021 – Jun 2026) | $136 | $133 |
| Since data start (Jul 2019 – Jun 2026) | $162 | $169 |
FKIQX Trailing Returns
Total returns to Jun 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +4.71% |
| 1 year | +11.43% |
| 3 years (annualised) | +9.58% |
| 5 years (annualised) | +6.27% |
FKIQX Annual Returns
Calendar-year total returns of Franklin Income Fund, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jun) | +4.71% |
| 2025 | +12.17% |
| 2024 | +7.03% |
| 2023 | +8.54% |
| 2022 | −5.61% |
| 2021 | +17.57% |
| 2020 | +3.46% |
| 2019 (Jul–Dec) | +3.49% |
FKIQX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +2.9% | +2.0% | −1.9% | +1.6% | +0.4% | −0.3% | — | — | — | — | — | — |
| 2025 | +1.7% | +1.7% | −0.8% | −1.7% | +1.8% | +2.6% | +0.4% | +2.5% | +0.8% | +0.4% | +1.3% | +0.7% |
| 2024 | 0.0% | −0.4% | +2.7% | −1.7% | +2.7% | 0.0% | +3.1% | +1.7% | +1.7% | −1.2% | +1.3% | −2.9% |
| 2023 | +4.5% | −2.1% | +0.9% | +1.3% | −2.6% | +1.8% | +1.8% | −1.3% | −3.1% | −2.7% | +6.2% | +4.1% |
| 2022 | +0.4% | −1.2% | +2.0% | −4.0% | +1.7% | −6.6% | +4.0% | −2.6% | −5.7% | +4.2% | +4.5% | −1.5% |
| 2021 | 0.0% | +3.0% | +4.7% | +2.0% | +1.6% | 0.0% | +0.4% | +1.2% | −1.6% | +2.8% | −2.0% | +4.6% |
| 2020 | −0.4% | −4.8% | −11.4% | +4.7% | +2.5% | 0.0% | +2.0% | +2.4% | −1.4% | −0.5% | +9.3% | +2.7% |
| 2019 | — | — | — | — | — | — | −0.4% | −0.9% | +1.8% | +0.4% | 0.0% | +2.6% |
FKIQX Risk
Risk measures from monthly returns over Jul 2023 – Jun 2026.
- 3-year volatility (annualised): 7.06%
- 3-year Sharpe ratio: 0.72 (vs 4.5% risk-free rate)
- Best month: +6.18% (Nov 2023)
- Worst month: −3.08% (Sep 2023)
FKIQX Fund Flows
Monthly money in and out of Franklin Income Fund, from SEC Form N-PORT.
- 12-month net flow: $938.4M
- 12-month gross sales (incl. reinvestments): $13.3B
- Sales ÷ redemptions: 1.08×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jun 2026 | $1.1B | $996.5M | $71.0M |
| May 2026 | $1.1B | $1.0B | $76.7M |
| Apr 2026 | $1.1B | $1.0B | $92.6M |
| Mar 2026 | $1.1B | $1.1B | $4.2M |
| Feb 2026 | $1.1B | $956.2M | $192.8M |
| Jan 2026 | $1.2B | $1.1B | $74.4M |
| Dec 2025 | $1.3B | $1.1B | $269.0M |
| Nov 2025 | $1.0B | $942.7M | $76.0M |
| Oct 2025 | $1.1B | $1.0B | $57.0M |
| Sep 2025 | $1.0B | $976.0M | $68.0M |
| Aug 2025 | $1.1B | $1.1B | −$4.1M |
| Jul 2025 | $993.0M | $1.0B | −$39.1M |
FKIQX Assets Under Management
Net assets of Franklin Income Fund by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-06-30 | $79.23B |
| 2026-03-31 | $78.63B |
| 2025-12-31 | $77.25B |
| 2025-09-30 | $76.17B |
| 2025-06-30 | $74.23B |
| 2025-03-31 | $73.51B |
| 2024-12-31 | $72.96B |
| 2024-09-30 | $75.74B |
| 2024-06-30 | $72.29B |
| 2024-03-31 | $73.09B |
| 2023-12-31 | $72.60B |
| 2023-09-30 | $69.16B |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.